The Impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients

Table 4

The differential values (DV) of clinical characteristics per SLC22A1 rs594709 and SLC47A1 rs2289669 genotypes.

SLC47A1 rs2289669	SLC22A1 rs594709 AA ()		value	SLC22A1 rs594709 GA/GG ()		value
	AA ()	GA + GG ()		AA ()	GA + GG ()
FBG (mmol/L)			0.015			0.641
PBG (mmol/L)			0.067			0.310
FINS (mU/L)			0.252			0.865
PINS (mU/L)			0.041			0.799
HbA1c (%)			0.487			0.778
TG (mmol/L)			0.061			0.466
TChol (mmol/L)			0.197			0.013
LDL-C (mmol/L)			0.148			0.228
HDL-C (mmol/L)			0.134			0.205
HOMA-IR			0.014			0.841
HOMA-IS			0.440			0.345
HOMA-B			0.441			0.149
QUICKI			0.447			0.437

BMI: body mass index; FBG: fasting blood glucose; PBG: postprandial blood glucose; FINS: fasting insulin; PINS: postprandial insulin; HbA1c: glycosylated haemoglobin; TG: triglycerides; TChol: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; HOMA-IR: homeostasis model assessment of insulin resistance; HOMA-IS: homeostasis model assessment of insulin sensitivity; HOMA-B: homeostasis model assessment of β-cell function; QUICKI: quantitative insulin sensitivity check index.
for comparison of AA genotype with GA/GG genotype of SLC47A1 rs2289669 polymorphism in SLC22A1 rs594709 AA genotyped T2DM patients, adjusted for age, sex, and BMI, in dominant model.
for comparison of AA genotype with GA/GG genotype of SLC47A1 rs2289669 polymorphism in SLC22A1 rs594709 GA or GG genotyped T2DM patients, adjusted for age, sex, and BMI, in dominant model.